Dual targeting with 212Pb/224Ra is particularly promising since most late-stage prostate cancers have skeletal involvement, and 212Pb-PSMA ligand and 224Ra represent two different targeting approaches in one radiopharmaceutical solution. The gene discussed is FOLH1; the disease is prostate cancer.